T3 Companies’s Intensity Therapeutics INTS Stock Holding History

T3 Companies’s Portfolio INTS Stock Details INTS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-544	Closed	-$5.58K	–	194
2025 Q4	$5.58K	Buy	+544	New	+$5.52K	0.01%	171

Other funds holding INTS

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Sapient Capital Indianapolis, Indiana $7.64B AUM 51.51% 1-Year Est. Return

NCNMGF

Nano-Cap New Millennium Growth Fund Staten Island, New York $107M AUM

Sentinus LLC Oak Brook, Illinois $1.11B AUM 17.13% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

MFIM

Mesirow Financial Investment Management Chicago, Illinois $6.18B AUM 18.43% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

NewEdge Advisors New Orleans, Louisiana $27.7B AUM 22.98% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

T3 Companies's INTS Position: Q1 2026 in Review

T3 Companies sold out of Intensity Therapeutics (INTS) in Q1 2026, closing a stake of 544 shares — an estimated $5.58K sold.

T3 Companies first reported a position in INTS in Q4 2025 and held it in 1 quarter. The position peaked at $5.58K in Q4 2025. 13 funds tracked by Wall St. Rank hold INTS as of Q1 2026.

T3 Companies reported no remaining Intensity Therapeutics position as of Q1 2026 after selling out during the quarter.
T3 Companies sold 544 Intensity Therapeutics shares in Q1 2026, an estimated $5.58K.
T3 Companies first reported a position in Intensity Therapeutics in Q4 2025 and held it in 1 quarter.
T3 Companies's Intensity Therapeutics position peaked at $5.58K in Q4 2025.
13 funds tracked by Wall St. Rank held Intensity Therapeutics as of Q1 2026.

Based on T3 Companies's 13F filing for Q1 2026, filed 7 May 2026.